Background: Addressing the Limitations of Standard BRCA1/2 Mutation Analysis and the Dynamic Time-Series Omics Data Bottleneck in Ovarian and Breast Cancer R&D

Existing linear and static DNA analysis standard guidelines fail to overcome critical blind spots in the genome damage repair system, such as cellular dissociation-induced structural collapse noise, and clonal heterogeneity and interspecies evolutionary differences within the tumor microenvironment. In particular, they cannot track and control dynamic signaling changes, such as the restoration of homologous recombination repair function or resistance feedback flux, which occur in real-time in patients after in silico computational environments, leading to data barriers that prevent the maintenance of optimal prophylactic concentrations during targeted drug administration and allow for cancer cell engraftment and metastasis. This approach is limited to statically detecting variations in the genome sequence, failing to capture the spatiotemporal dynamics of the ever-changing homologous recombination deficiency (HRD) matrix, and causing a bottleneck in genetic information that leads to discrepancies between patient's actual clinical phenotypes in new drug R&D pipelines.

Discovery: Implementation of a Homologous Recombination Deficiency (HRD) Computational Algorithm and Demonstration of Single-Cell Resolution Multi-Dimensional Genetic Gradient Tensor Synchronization

This R&D architecture is based on a large-scale multi-omics data matrix accumulated over the past 30 years, tracking homologous recombination deficiency indicators in real-time at single-cell resolution and coordinating the thermodynamic free energy of molecular docking and interactions. The binding patterns of DNA double-strand breaks were proactively calculated in silico using differential equation-based rate constants to quantify changes in homologous recombination repair rates in heterogeneous cell populations. In particular, a correction coefficient model that mathematically completely offsets batch effects between different sequencing platforms was introduced, achieving a precision that disruptively surpasses the limitations of conventional simple sequence alignment models. The topological phase variation curves of downstream transcriptome networks were successfully elucidated, verifying the molecular biological structural integrity for BRCA protein complex formation and demonstrating the actual transcriptional activity of cell growth inhibitory signals.

Establishment of a Model for Coordinating Homologous Recombination Repair Pathways and Reversible Genome Homeostasis Precision Layering

Using a multi-omics integrated matrix, a computational model was developed to precisely stratify patients based on BRCA-derived genomic functional loss. By artificially clamping the rate-limiting step constants of repair pathways within cancer cells, a technology was established to induce reversible genomic homeostasis or, conversely, to accumulate lethal damage and induce synthetic lethality. By coordinating the dynamic parameter changes of damage repair enzymes, the action of target molecules was up-regulated and down-regulated, suppressing the abnormal adaptive stress response of cancer cells and inducing them to enter an autonomous apoptosis pathway, thereby establishing a computational backbone architecture and achieving clinical prediction success rates.

Prospects: Establishing a Programmable Tumor Genomics Standard and Launching a Next-Generation IND Digital Governance System

Tumor genomics research and diagnostic R&D governance will be completely reset from the existing static, post-treatment system to a programmable prevention infrastructure based on AI-powered multi-dimensional tensor models. This is directly linked to the expansion of the $3 billion PARP inhibitor market pipeline, including AstraZeneca's Olaparib (Lynparza) and GSK's Niraparib. A computational moat is established by organically linking genetic gradient correction coefficients in the high-throughput screening stage to eliminate batch-to-batch variations in the cGMP production stage. Ultimately, it will fully meet the requirements of digital healthcare-based companion diagnostics (CDx), disruptively shorten the timelines for FDA clinical trial approval and product licensing in the United States, and establish itself as a standard technology asset for genetic cancer precision diagnostics.